You are here
CURE Pharmaceutical to Present on the Increased Bioavailability for Cannabinoids Due to New Delivery Technologies at O’Cannabiz Conference
LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced that CEO Rob Davidson will be presenting at the O’Cannabiz Conference & Expo on June 9 at 2:50 PM ET in Toronto, Canada. Davidson will discuss “Maximizing and Understanding the Benefits of Proprietary Delivery Technologies for Increasing Bioavailability of Cannabinoid Molecules” and will meet with investors at the conference.
“The most common delivery methods for pharmaceutical cannabis such as capsules, tinctures and oils are extremely limited,” said Davidson. “Cannabinoid molecules have a relatively low bioavailability rate when ingested because only a fraction of the ingredient makes it into the blood stream. New drug delivery technologies, such as our CUREfilm™ oral thin film, make medications more effective.”
O’Cannabiz is dedicated to exploring the latest regulation, industry standards and best practices for medicinal and recreational marijuana. Davidson will be highlighting various drug delivery technologies including transdermal, nasal and various oral options that can help with increased bioavailability for cannabinoid molecules.
Davidson also will discuss the company’s research of cannabinoid molecules, such as their work with Therapix Biosciences on cannabinoid-based products for sleep disorders and their research with Technion-Israel Institute of Technology on cancer-fighting cannabinoids.
If you would like to schedule a meeting with CURE Pharmaceutical, please contact Aaron Wood at email@example.com.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.